MYBPHL

Summary

MYBPHL (myosin binding protein H like, HGNC:30434) is a protein-coding gene on chromosome 1p13.3, encoding Myosin-binding protein H-like (A2RUH7). Myosin-binding protein which plays a role in cardiac function.

This gene encodes a protein with two immunoglobulin superfamily domains and a fibronectin 3 domain. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 343263 — RefSeq curated summary.

At a glance

• Gene–disease (curated): familial dilated cardiomyopathy (Limited, GenCC)
• GWAS associations: 9
• Clinical variants (ClinVar): 99 total
• Phenotypes (HPO): 1
• MANE Select transcript: NM_001010985

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:30434
Approved symbol	MYBPHL
Name	myosin binding protein H like
Location	1p13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000221986
Ensembl biotype	protein_coding
OMIM	619807
Entrez	343263

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 7 protein_coding, 2 protein_coding_CDS_not_defined

ENST00000357155, ENST00000477962, ENST00000489706, ENST00000968916, ENST00000968917, ENST00000968918, ENST00000968919, ENST00000968920, ENST00000968921

RefSeq mRNA: 2 — MANE Select: NM_001010985 NM_001010985, NM_001265613

CCDS: CCDS30793

Canonical transcript exons

ENST00000357155 — 9 exons

Exon	Start	End
ENSE00001408480	109297050	109297189
ENSE00001424462	109306847	109307011
ENSE00001425062	109297422	109297617
ENSE00001425520	109298169	109298257
ENSE00001426460	109296783	109296942
ENSE00001428065	109296234	109296370
ENSE00001428624	109292365	109292588
ENSE00003559518	109294206	109294249
ENSE00003578984	109295111	109295297

Expression profiles

Bgee: expression breadth ubiquitous, 123 present calls, max score 97.73.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 0.4076 / max 157.7508, expressed in 67 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
13686	0.3853	61
13687	0.0223	9

Top tissues by expression

131 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right atrium auricular region	UBERON:0006631	97.73	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	92.44	silver quality
Ammon’s horn	UBERON:0001954	73.17	gold quality
pituitary gland	UBERON:0000007	72.22	gold quality
Brodmann (1909) area 9	UBERON:0013540	71.61	gold quality
primary visual cortex	UBERON:0002436	71.55	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	71.35	gold quality
right uterine tube	UBERON:0001302	70.49	gold quality
prefrontal cortex	UBERON:0000451	70.09	gold quality
cerebral cortex	UBERON:0000956	70.04	gold quality
right frontal lobe	UBERON:0002810	69.93	gold quality
frontal cortex	UBERON:0001870	69.90	gold quality
anterior cingulate cortex	UBERON:0009835	69.17	gold quality
adenohypophysis	UBERON:0002196	68.69	gold quality
heart	UBERON:0000948	68.57	gold quality
superior frontal gyrus	UBERON:0002661	68.56	gold quality
gastrocnemius	UBERON:0001388	68.51	gold quality
substantia nigra	UBERON:0002038	66.67	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	66.32	gold quality
putamen	UBERON:0001874	65.23	gold quality
muscle of leg	UBERON:0001383	64.88	gold quality
brain	UBERON:0000955	63.01	gold quality
temporal lobe	UBERON:0001871	62.92	gold quality
amygdala	UBERON:0001876	62.78	gold quality
islet of Langerhans	UBERON:0000006	61.88	gold quality
caudate nucleus	UBERON:0001873	61.08	gold quality
hindlimb stylopod muscle	UBERON:0004252	60.93	gold quality
upper lobe of left lung	UBERON:0008952	59.67	gold quality
lower esophagus mucosa	UBERON:0035834	59.53	gold quality
esophagogastric junction muscularis propria	UBERON:0035841	58.85	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.09

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

7 targeting MYBPHL, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3119	99.92	71.34	2390
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-1224-5P	99.48	65.59	803
HSA-MIR-4443	98.02	66.25	1928
HSA-MIR-1914-5P	97.83	66.21	807
HSA-MIR-6872-3P	97.08	66.99	750
HSA-MIR-4448	97.04	66.22	752

Literature-anchored findings (GeneRIF, showing 3)

• MYBPHL truncations may increase risk for human arrhythmias and cardiomyopathy. (PMID:28778945)
• Myosin binding protein H-like (MYBPHL): a promising biomarker to predict atrial damage. (PMID:31292467)
• A proof-of-concept study for the pathogenetic role of enhancer hypomethylation of MYBPHL in multiple myeloma. (PMID:33772052)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mybphl	ENSMUSG00000068745
rattus_norvegicus	Mybphl	ENSRNOG00000037082
drosophila_melanogaster	mtgo	FBGN0259735
caenorhabditis_elegans		WBGENE00007944

Paralogs (11): MYOM2 (ENSG00000036448), FNDC3B (ENSG00000075420), MYBPC2 (ENSG00000086967), MYOM1 (ENSG00000101605), FNDC3A (ENSG00000102531), OBSL1 (ENSG00000124006), MYBPH (ENSG00000133055), MYBPC3 (ENSG00000134571), MYOM3 (ENSG00000142661), IGSF22 (ENSG00000179057), MYBPC1 (ENSG00000196091)

Protein

Protein identifiers

Myosin-binding protein H-like — A2RUH7 (reviewed: A2RUH7)

All UniProt accessions (1): A2RUH7

UniProt curated annotations — full annotation on UniProt →

Function. Myosin-binding protein which plays a role in cardiac function. Seems to regulate conduction in the atria and ventricular conduction systems.

Subcellular location. Cytoplasm. Myofibril. Sarcomere.

Tissue specificity. Expressed in heart, with higher expression in the atria. Expressed in left atrium and ventricle, arteria mammaria interna and skeletal muscle. Expressed specifically en the left atrium.

Similarity. Belongs to the immunoglobulin superfamily. MyBP family.

Isoforms (2)

UniProt ID	Names	Canonical?
A2RUH7-1	1	yes
A2RUH7-2	2

RefSeq proteins (2): NP_001010985, NP_001252542 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003598	Ig_sub2	Domain
IPR003599	Ig_sub	Domain
IPR003961	FN3_dom	Domain
IPR007110	Ig-like_dom	Domain
IPR013098	Ig_I-set	Domain
IPR013783	Ig-like_fold	Homologous_superfamily
IPR036116	FN3_sf	Homologous_superfamily
IPR036179	Ig-like_dom_sf	Homologous_superfamily
IPR050964	Striated_Muscle_Regulatory	Family

Pfam: PF00041, PF07679

UniProt features (11 total): domain 3, sequence variant 2, modified residue 2, chain 1, region of interest 1, disulfide bond 1, splice variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-A2RUH7-F1	86.64	0.74

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (2): 38, 321

Disulfide bonds (1): 282–333

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 22 (showing top): GOBP_EMBRYO_DEVELOPMENT_ENDING_IN_BIRTH_OR_EGG_HATCHING, GOBP_IN_UTERO_EMBRYONIC_DEVELOPMENT, GOBP_EMBRYO_DEVELOPMENT, GOCC_MYOFILAMENT, PEDRIOLI_MIR31_TARGETS_DN, GOCC_SUPRAMOLECULAR_COMPLEX, GOCC_SUPRAMOLECULAR_POLYMER, DACH1_TARGET_GENES, HOXD1_TARGET_GENES, MAFG_TARGET_GENES, MEF2D_TARGET_GENES, GSE14308_TH2_VS_NAIVE_CD4_TCELL_DN, CUI_DEVELOPING_HEART_5TH_WEEK_VENTRICULAR_CARDIOMYOCYTE, DESCARTES_MAIN_FETAL_CARDIOMYOCYTES, NKX2_5_TARGET_GENES

GO Biological Process (2): in utero embryonic development (GO:0001701), biological_process (GO:0008150)

GO Molecular Function (2): molecular_function (GO:0003674), protein binding (GO:0005515)

GO Cellular Component (3): sarcomere (GO:0030017), myofilament (GO:0036379), cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
myofibril	2
chordate embryonic development	1
binding	1
intracellular anatomical structure	1

Protein interactions and networks

STRING

422 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
MYBPHL	PSRC1	Q6PGN9	797
MYBPHL	CELSR2	Q9HCU4	718
MYBPHL	SORT1	Q99523	623
MYBPHL	SYPL2	Q5VXT5	491
MYBPHL	TACC2	O95359	437
MYBPHL	PRPF19	Q9UMS4	435
MYBPHL	MACO1	Q8N5G2	422
MYBPHL	CASP8AP2	Q9UKL3	422
MYBPHL	AMHR2	Q16671	409
MYBPHL	OR10P1	Q8NGE3	400
MYBPHL	C22orf42	Q6IC83	395
MYBPHL	PSMA5	P28066	389
MYBPHL	PRR32	B1ATL7	370
MYBPHL	CCS	O14618	368
MYBPHL	FAM177B	A6PVY3	366

IntAct

46 interactions, top by confidence:

A	B	Type	Score
MYBPHL	GFAP	psi-mi:“MI:0915”(physical association)	0.720
MYBPHL	FHL3	psi-mi:“MI:0915”(physical association)	0.560
FHL3	MYBPHL	psi-mi:“MI:0915”(physical association)	0.560
MYBPHL	MALSU1	psi-mi:“MI:0915”(physical association)	0.560
CALR	MYBPHL	psi-mi:“MI:0915”(physical association)	0.560
CASP6	MYBPHL	psi-mi:“MI:0915”(physical association)	0.560
DLST	MYBPHL	psi-mi:“MI:0915”(physical association)	0.560
LAMP2	MYBPHL	psi-mi:“MI:0915”(physical association)	0.560
RAN	MYBPHL	psi-mi:“MI:0915”(physical association)	0.560
MYBPHL	TP53BP2	psi-mi:“MI:0915”(physical association)	0.560
CDK5R1	MYBPHL	psi-mi:“MI:0915”(physical association)	0.560
MYBPHL	JPH3	psi-mi:“MI:0915”(physical association)	0.560
MYBPHL	NEK7	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (15): MYBPHL (Two-hybrid), MYBPHL (Two-hybrid), GFPT2 (Affinity Capture-MS), TTC19 (Affinity Capture-MS), CASK (Affinity Capture-MS), PLEKHA6 (Affinity Capture-MS), MYBPHL (Two-hybrid), CASK (Affinity Capture-MS), PLEKHA6 (Affinity Capture-MS), MYBPHL (Two-hybrid), MYBPHL (Two-hybrid), MYBPHL (Two-hybrid), MYBPHL (Two-hybrid), DPCD (Affinity Capture-MS), MYBPHL (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A087WV53, A1CS92, A2ABU4, A2Q908, A2RUH7, A4QZL9, D3ZHA0, O01761, O70468, O75369, O88599, P05548, P11275, P11730, P11798, P13466, P21333, P56276, P56741, P70402, P79280, Q05623, Q13177, Q13203, Q13557, Q14315, Q2GM53, Q2HJF7, Q2URB7, Q5FW53, Q5PQM4, Q5RCC4, Q5VTT5, Q5ZJJ9, Q5ZKI0, Q62422, Q63518, Q6C1H8, Q6P686, Q6PHZ2

Diamond homologs: A0A087WV53, A2AAJ9, A2ASS6, A2RUH7, O75147, O94856, O94898, P05548, P52179, P54296, P97685, Q00872, Q23551, Q52KR2, Q5VST9, Q62234, Q80W87, Q810U3, Q8WX93, Q92626, A2CG49, F1M0Z1, O08775, O60229, O70468, O75962, O88599, P11799, P16419, P35918, P56741, P70402, P97924, Q05623, Q0KL02, Q13203, Q14324, Q14896, Q15746, Q5FW53

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

99 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	74
Likely benign	3
Benign	21

Top pathogenic / likely-pathogenic (0)

SpliceAI

1567 predictions. Top by Δscore:

Variant	Effect	Δscore
1:109296777:CCTTA:C	donor_loss	1.0000
1:109296778:CTTA:C	donor_loss	1.0000
1:109296779:TTACC:T	donor_loss	1.0000
1:109296780:TACCT:T	donor_loss	1.0000
1:109296781:A:AC	donor_gain	1.0000
1:109296781:A:C	donor_loss	1.0000
1:109296781:ACCTG:A	donor_gain	1.0000
1:109296782:C:CC	donor_gain	1.0000
1:109296782:CCTG:C	donor_gain	1.0000
1:109296782:CCTGC:C	donor_gain	1.0000
1:109296938:CACAG:C	acceptor_gain	1.0000
1:109296939:ACAG:A	acceptor_gain	1.0000
1:109296940:CAG:C	acceptor_gain	1.0000
1:109296940:CAGC:C	acceptor_gain	1.0000
1:109296941:AG:A	acceptor_gain	1.0000
1:109296941:AGCTG:A	acceptor_loss	1.0000
1:109296943:C:CC	acceptor_gain	1.0000
1:109296952:C:CT	acceptor_gain	1.0000
1:109296953:G:T	acceptor_gain	1.0000
1:109294250:C:CC	acceptor_gain	0.9900
1:109295105:CCTTA:C	donor_loss	0.9900
1:109295106:CTTAC:C	donor_loss	0.9900
1:109295107:TTAC:T	donor_loss	0.9900
1:109295108:TA:T	donor_loss	0.9900
1:109295293:TTGGG:T	acceptor_gain	0.9900
1:109296782:CCT:C	donor_gain	0.9900
1:109296952:C:T	acceptor_gain	0.9900
1:109306888:C:CA	donor_gain	0.9900
1:109295295:GGGC:G	acceptor_loss	0.9800
1:109295296:GG:G	acceptor_gain	0.9800

AlphaMissense

2283 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
1:109295154:G:C	N337K	1.000
1:109295154:G:T	N337K	1.000
1:109295174:A:C	Y331D	0.999
1:109295212:A:G	L318P	0.999
1:109295283:C:A	W294C	0.999
1:109295283:C:G	W294C	0.999
1:109295285:A:G	W294R	0.999
1:109295285:A:T	W294R	0.999
1:109296313:A:G	F263S	0.999
1:109296860:C:G	R218P	0.999
1:109297485:A:C	Y123D	0.999
1:109297591:C:A	W87C	0.999
1:109297591:C:G	W87C	0.999
1:109297593:A:G	W87R	0.999
1:109297593:A:T	W87R	0.999
1:109295166:G:C	C333W	0.998
1:109295173:T:G	Y331S	0.998
1:109295284:C:G	W294S	0.998
1:109296255:G:C	C282W	0.998
1:109296863:A:G	F217S	0.998
1:109297072:T:G	Q183P	0.998
1:109297124:A:G	W166R	0.998
1:109297124:A:T	W166R	0.998
1:109297478:A:G	L125P	0.998
1:109297530:A:G	S108P	0.998
1:109297592:C:G	W87S	0.998
1:109298185:A:G	L73P	0.998
1:109295168:A:G	C333R	0.997
1:109295174:A:T	Y331N	0.997
1:109295281:A:G	L295P	0.997

dbSNP variants (sampled 300 via entrez): RS1000104328 (1:109306022 A>T), RS1000107586 (1:109299101 C>T), RS1000277169 (1:109296424 G>A,C), RS1000417720 (1:109301950 A>G), RS1000485337 (1:109301829 A>G), RS1000523963 (1:109301705 C>A,T), RS1000705403 (1:109307447 C>G), RS1000831649 (1:109306206 C>G,T), RS1001001994 (1:109307715 G>A), RS1001244079 (1:109292521 T>C), RS1001358738 (1:109297320 G>A), RS1001418242 (1:109303235 A>G), RS1001496288 (1:109308759 TG>T), RS1001533866 (1:109302909 G>A), RS1001808480 (1:109297475 C>T)

Disease associations

OMIM: gene MIM:619807 | disease phenotypes: MIM:236750, MIM:601144

GenCC curated gene-disease

Disease	Classification	Inheritance
familial dilated cardiomyopathy	Limited	Unknown

Mondo (6): non-immune hydrops fetalis (MONDO:0009369), long QT syndrome (MONDO:0002442), hypertrophic cardiomyopathy (MONDO:0005045), cardiomyopathy (MONDO:0004994), Brugada syndrome (MONDO:0015263), familial dilated cardiomyopathy (MONDO:0016333)

Orphanet (4): Non-immune hydrops fetalis (Orphanet:363999), Rare hypertrophic cardiomyopathy (Orphanet:217569), Brugada syndrome (Orphanet:130), Rare cardiomyopathy (Orphanet:167848)

HPO phenotypes

1 total (1 of 1 shown, HPO-id order):

HPO	Term
HP:0001639	Hypertrophic cardiomyopathy

GWAS associations

9 associations (top):

Study	Trait	p-value
GCST005109_1	Progranulin levels	6.000000e-50
GCST005316_310	Intelligence (MTAG)	4.000000e-11
GCST006269_393	General cognitive ability	2.000000e-10
GCST007045_13	PR interval	2.000000e-09
GCST008059_86	Estimated glomerular filtration rate	9.000000e-20
GCST010243_178	Apolipoprotein B levels	7.000000e-44
GCST010243_20	Apolipoprotein B levels	4.000000e-13
GCST010243_230	Apolipoprotein B levels	4.000000e-69
GCST010321_99	PR interval	1.000000e-10

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0004625	progranulin measurement
EFO:0004337	intelligence
EFO:0004462	PR interval
EFO:0004615	apolipoprotein B measurement

MeSH disease descriptors (5)

Descriptor	Name	Tree numbers
D053840	Brugada Syndrome	C14.280.067.322; C14.280.123.250; C16.320.100
D009202	Cardiomyopathies	C14.280.238
D002312	Cardiomyopathy, Hypertrophic	C14.280.238.100; C14.280.484.048.750.070.160
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547
C536231	familial dilated cardiomyopathy (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

13 total (human), top 13 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases methylation	2
bufotalin	decreases expression	1
benzo(e)pyrene	increases methylation	1
CGP 52608	affects binding, increases reaction	1
theaflavin-3,3’-digallate	affects expression	1
Sunitinib	increases expression	1
Malathion	increases expression	1
Methapyrilene	increases methylation	1
Mustard Gas	increases expression	1
Smoke	decreases expression	1
Triclosan	decreases expression	1
Urethane	decreases expression	1
Aflatoxin B1	increases methylation	1

Clinical trials (associated diseases)

303 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01798992	PHASE4	COMPLETED	Effect of Beta-blockers on Structural Remodeling and Gene Expression in the Failing Human Heart
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT00879060	PHASE4	COMPLETED	Clinical and Therapeutic Implications of Fibrosis in Hypertrophic Cardiomyopathy
NCT01721967	PHASE4	COMPLETED	Ranolazine for the Treatment of Chest Pain in HCM Patients
NCT02948998	PHASE4	UNKNOWN	Evaluating the Effect of Spironolactone on Hypertrophic Cardiomyopathy
NCT03249272	PHASE4	TERMINATED	Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve
NCT04133532	PHASE4	COMPLETED	Effect of Metoprolol in Post Alcohol Septal Ablation Patients With Hypertrophic Cardiomyopathy
NCT06401343	PHASE4	RECRUITING	Use of SGLT2i in noHCM With HFpEF
NCT07103655	PHASE4	NOT_YET_RECRUITING	The Therapeutic Value of Mavacamten in Hypertrophic Cardiomyopathy With Mid-to-Apical Left Ventricular Obstruction
NCT07600177	PHASE4	RECRUITING	Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT00348530	PHASE4	UNKNOWN	Carvedilol Versus Verapamil in Chronic Heart Failure Secondary to Non-Ischemic Cardiomyopathy
NCT00371891	PHASE4	COMPLETED	Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS)
NCT00401856	PHASE4	COMPLETED	CMR to Assess Fibrosis in Cardiomyopathy Using Eplerenone
NCT00559338	PHASE4	COMPLETED	Impact of Nesiritide Infusion for Decompensated Heart Failure in the Emergency Department
NCT00606775	PHASE4	UNKNOWN	The Preventive Efficacy of Carvedilol on Cardiac Dysfunction in Duchenne Muscular Dystrophy
NCT00317967	PHASE3	COMPLETED	Study to Determine if Atorvastatin Reduces Size and Stiffness of Muscle in the Left Ventricle of the Heart
NCT00698074	PHASE3	UNKNOWN	Diastolic Ventricular Interaction and the Effects of Biventricular Pacing in Hypertrophic Cardiomyopathy
NCT00821353	PHASE3	COMPLETED	Antiarrhythmic Therapy Versus Catheter Ablation for Atrial Fibrillation in Hypertrophic Cardiomyopathy
NCT02431221	PHASE3	WITHDRAWN	Efficacy, Safety, and Tolerability of Perhexiline in Subjects With Hypertrophic Cardiomyopathy and Heart Failure
NCT03470545	PHASE3	COMPLETED	Clinical Study to Evaluate Mavacamten (MYK-461) in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT05174416	PHASE3	COMPLETED	A Study to Evaluate the Efficacy and Safety of Mavacamten in Chinese Adults With Symptomatic Obstructive HCM
NCT05182658	PHASE3	ACTIVE_NOT_RECRUITING	Empagliflozin in Hypertrophic Cardiomyopathy
NCT05186818	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM
NCT05767346	PHASE3	COMPLETED	Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol Succinate in Adults With Symptomatic oHCM
NCT06116968	PHASE3	COMPLETED	An Open-Label Study of Aficamten for Chinese Patients With Symptomatic oHCM
NCT06873828	PHASE3	NOT_YET_RECRUITING	Evaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter MonitoringEvaluation of the Efficacy and Safety of Wearable ECG (AT-Patch) in Patients With Hypertrophic Cardiomyopathy Requiring 48-Hour Holter Monitoring
NCT07021976	PHASE3	RECRUITING	A Phase III Trial of HRS-1893 in Patients With Obstructive Hypertrophic Cardiomyopathy
NCT07023341	PHASE3	ACTIVE_NOT_RECRUITING	A Study to Learn More About How Well Aficamten Works in Japanese Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy
NCT07202897	PHASE3	NOT_YET_RECRUITING	LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.
NCT02033278	PHASE2	TERMINATED	Infusion Intracoronary of Mononuclear Autologous Adult no Expanded Stem Cells of Bone Marrow on Functional Recovery in Patients With Idiopathic Dilated Cardiomyopathy and Heart Failure.
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00001631	PHASE2	COMPLETED	Study of Blood Flow in Heart Muscle
NCT00001894	PHASE2	COMPLETED	A Comparison of Two Treatments: Pacemaker and Percutaneous Transluminal Septal Ablation for Hypertrophic Cardiomyopathy
NCT00001960	PHASE2	COMPLETED	Studying the Effectiveness of Pacemaker Therapy in Children Who Have Thickened Heart Muscle
NCT00011076	PHASE2	COMPLETED	Pirfenidone to Treat Hypertrophic Cardiomyopathy